doi: 10.1016/S1470-2045(22)00064-X.
Retraction and republication-Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Affiliations
- PMID: 35241252
- DOI: 10.1016/S1470-2045(22)00064-X
Item in Clipboard
Retraction and republication-Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Lancet Oncol.
2022 Mar.
Corrected and republished in
-
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.Lancet Oncol. 2022 Mar;23(3):e105-e115. doi: 10.1016/S1470-2045(22)00066-3. Lancet Oncol. 2022. PMID: 35240087 Clinical Trial.
No abstract available
Retraction of
-
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.Lancet Oncol. 2021 Aug;22(8):1093-1102. doi: 10.1016/S1470-2045(21)00286-2. Epub 2021 Jul 5. Lancet Oncol. 2021. Retraction in: Lancet Oncol. 2022 Mar;23(3):330. doi: 10.1016/S1470-2045(22)00064-X. PMID: 34237249 Retracted. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
